The Hakka population in southern China exhibits a high prevalence of CYP2C19 intermediate and poor metabolizers, highlighting the potential need for personalized antiplatelet therapy such as clopidogrel.
No takes yet. Share an insight, caveat, or question.
May inform genotype-guided clopidogrel use in Hakka patients; hypothesis-generating pending outcome trials.
Zhong et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: